Chand  Khanna, D.V.M., Ph.D.
Chand Khanna, D.V.M., Ph.D.
Senior Scientist (Contr)

Center for Cancer Research
National Cancer Institute

Building 37, Suite 2144
Bethesda, MD 20892
301 594-3406

Dr. Chand Khanna's primary area of research is the biology and treatment of cancer metastasis. Dr. Khanna has been able to couple his training in veterinary oncology with his interests in cancer research through the development of the Comparative Oncology Program, within the NCI Center for Cancer Research.

Areas of Expertise
1) cancer metastasis, 2) cancer biology, 3) veterinary oncology

Comparative Oncology Program

Our approach to the problem of metastasis is founded in the development, characterization and use of relevant in vivo (animal) models of metastasis. These models include transplantable tumor models, genetically engineered mouse models of metastasis, and naturally occurring cancers that develop in companion animals. The study of companion animal cancers is facilitated through the CCR's Comparative Oncology Program. The use of several model systems to study problems in metastasis provides an opportunity to emphasize the strengths and minimize the weaknesses of a single model system.

A central mission of the NCI Center for Cancer Research (CCR) is the development and delivery of novel cancer treatment strategies for cancer patients. A significant hurdle in the translation of information from the laboratory to the clinic is the availability of appropriate preclinical cancer models. Through a number of new initiatives the CCR has created an essential infrastructure to facilitate the translational research process. An example of this effort is the CCR Comparative Oncology Program. Comparative oncology refers to the study of naturally occurring cancers, primarily in companion animals. The Comparative Oncology Program includes companion animals in the study of the treatment and biology of cancer.

Goals

1)  Develop an essential reagent kit for the study of comparative models in translational and biology-based research.  Specific reagents/resources include:

  • Canine oligonucleotide microarray.  Optimized techniques and normal tissue expression standards for both a first-generation and, more recently, a second-generation canine oligonucleotide microarray have been completed and initiated.  This microarray is currently available through Affymetrix.
  • Serum proteomics (SELDI-TOFF).  Conditions for canine serum proteomic analysis have been optimized.
  • Validated antibody database.  A database of validated antibodies for use in canine tissues is being developed within the Comparative Oncology Program in collaboration with commercial antibody vendors and Dr. David Goldstein, CCR.
  • Canine Comparative Oncology Genomics Consortium (CCOGC).  Using its neutral position, the Comparative Oncology Program has brought together a broad representation of parties (academic, industry, government) focused on the genetics and biology of cancer in dogs.  The efforts of the CCOGC were timely, given the release of the canine genome sequence in 2005.  The shared interests of the CCOGC will result in further genomics reagent/resource development and collaborative efforts that will characterize canine cancers as molecular models of human disease.
  • Canine Cancer Biospecimen Repository. A biospecimen respository of frozen, and formalin-fixed tissues from dogs with cancer has been established. The collection of samples to populate this repository occurs through the clinical trials conducted by the Comparative Oncology Trials Consortium (COTC; discussed below) and the CCOGC.
  • Canine Cancer Tissue Arrays.  In collaboration with Dr. Stephen Hewit (CCR Tissue Array Research Program), a number of robust canine cancer tissue arrays have been developed.  These arrays include outcome-linked canine lymphoma, outcome-linked canine osteosarcoma, outcome-linked nasal carcinoma, and a multi-tumor canine tissue array.  Arrays in development include one for canine mammary cancer and one for canine prostate cancer. These array reagents have and will be useful for identifying therapeutic targets in canine cancers, and for the study of cancer and metastasis biology.

2) Develop a multi-center collaborative network with extramural comparative oncology programs.  Within this network we design, implement and manage pre-clinical trials involving pet animals that will evaluate novel therapeutic strategies for cancer:

  • Comparative Oncology Trial Consortium (COTC).  The Comparative Onoclogy Program has used its neutral leadership position to bring together several top-notch schools of veterinary medicine to collaborate as a multi-center clinical trial network.  This network works together through the Comparative Oncology Program to offer NCI investigators, the pharmaceutical industry, and the broader academic community the opportunity to inform their cancer drug development paths by using naturally occurring cancers in dogs as models for drug development.

3) Increase the awareness of the appropriate use of naturally occurring cancer models within the cancer research community.

Scientific Focus Areas:
Cancer Biology, Cell Biology
Selected Recent Publications
  1. El Touny LH, Vieira A, Mendoza A, Khanna C, Hoenerhoff MJ, Green JE
    J Clin Invest. 124: 156-68, 2014. [ Journal Article ]
  2. Paoloni M, Webb C, Mazcko C, Cherba D, Hendricks W, Lana S, Ehrhart EJ, Charles B, Fehling H, Kumar L, Vail D, Henson M, Childress M, Kitchell B, Kingsley C, Kim S, Neff M, Davis B, Khanna C, Trent J
    PLoS ONE. 9: e90028, 2014. [ Journal Article ]
  3. Heinecke JL, Ridnour LA, Cheng RY, Switzer CH, Lizardo MM, Khanna C, Glynn SA, Hussain SP, Young HA, Ambs S, Wink DA
    Proc Natl Acad Sci U S A. 111: 6323-8, 2014. [ Journal Article ]
  4. Mendoza A, Gharpure R, Dennis J, Webster JD, Smedley J, Khanna C
    J Am Assoc Lab Anim Sci . 52: 584-9, 2013. [ Journal Article ]
  5. Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, Barkauskas DA, Marina N, de Toledo SR, Petrilli AS, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter DJ, Malats N, Kogevinas M, Wacholder S, Troisi R, Helman L, Fraumeni JF, Yeager M, Hoover RN, Chanock SJ
    Nat Genet. 45: 799-803, 2013. [ Journal Article ]

Dr. Khanna is a graduate of the Western College of Veterinary Medicine in Saskatoon, Saskatchewan. His specialty training included a small animal medicine and surgery internship at the Ontario Veterinary College in Guelph, Ontario, followed by a residency in veterinary internal medicine and oncology at the University of Minnesota. Dr. Khanna is board-certified with the American College of Veterinary Internal Medicine (oncology). His training in cancer research includes a Ph.D. in pathobiology from the University of Minnesota, where he studied the immunotherapy of metastatic cancers, and a senior staff fellowship at the National Institutes of Health (NIH) in Bethesda Maryland. 

Dr. Khanna's primary area of interest is the biology and treatment of cancer metastasis. Dr. Khanna has been able to couple his training in veterinary oncology with his interests in cancer research through the development  of the Comparative Oncology Program, within the NCI Center for Cancer Research. This program aims to improve outcomes for cancer patients through the integration of pet animals with cancer into the study of cancer biology and treatment. Dr. Khanna is Chair of the Biology Subcommittee of the Children's Oncology Group, a founding member of the Canine Comparative Oncology and Genomics Consortium, and President-elect of the American College of Veterinary Internal Medicine - Oncology.

Summary

Dr. Chand Khanna's primary area of research is the biology and treatment of cancer metastasis. Dr. Khanna has been able to couple his training in veterinary oncology with his interests in cancer research through the development of the Comparative Oncology Program, within the NCI Center for Cancer Research.

Areas of Expertise
1) cancer metastasis, 2) cancer biology, 3) veterinary oncology

Research

Comparative Oncology Program

Our approach to the problem of metastasis is founded in the development, characterization and use of relevant in vivo (animal) models of metastasis. These models include transplantable tumor models, genetically engineered mouse models of metastasis, and naturally occurring cancers that develop in companion animals. The study of companion animal cancers is facilitated through the CCR's Comparative Oncology Program. The use of several model systems to study problems in metastasis provides an opportunity to emphasize the strengths and minimize the weaknesses of a single model system.

A central mission of the NCI Center for Cancer Research (CCR) is the development and delivery of novel cancer treatment strategies for cancer patients. A significant hurdle in the translation of information from the laboratory to the clinic is the availability of appropriate preclinical cancer models. Through a number of new initiatives the CCR has created an essential infrastructure to facilitate the translational research process. An example of this effort is the CCR Comparative Oncology Program. Comparative oncology refers to the study of naturally occurring cancers, primarily in companion animals. The Comparative Oncology Program includes companion animals in the study of the treatment and biology of cancer.

Goals

1)  Develop an essential reagent kit for the study of comparative models in translational and biology-based research.  Specific reagents/resources include:

  • Canine oligonucleotide microarray.  Optimized techniques and normal tissue expression standards for both a first-generation and, more recently, a second-generation canine oligonucleotide microarray have been completed and initiated.  This microarray is currently available through Affymetrix.
  • Serum proteomics (SELDI-TOFF).  Conditions for canine serum proteomic analysis have been optimized.
  • Validated antibody database.  A database of validated antibodies for use in canine tissues is being developed within the Comparative Oncology Program in collaboration with commercial antibody vendors and Dr. David Goldstein, CCR.
  • Canine Comparative Oncology Genomics Consortium (CCOGC).  Using its neutral position, the Comparative Oncology Program has brought together a broad representation of parties (academic, industry, government) focused on the genetics and biology of cancer in dogs.  The efforts of the CCOGC were timely, given the release of the canine genome sequence in 2005.  The shared interests of the CCOGC will result in further genomics reagent/resource development and collaborative efforts that will characterize canine cancers as molecular models of human disease.
  • Canine Cancer Biospecimen Repository. A biospecimen respository of frozen, and formalin-fixed tissues from dogs with cancer has been established. The collection of samples to populate this repository occurs through the clinical trials conducted by the Comparative Oncology Trials Consortium (COTC; discussed below) and the CCOGC.
  • Canine Cancer Tissue Arrays.  In collaboration with Dr. Stephen Hewit (CCR Tissue Array Research Program), a number of robust canine cancer tissue arrays have been developed.  These arrays include outcome-linked canine lymphoma, outcome-linked canine osteosarcoma, outcome-linked nasal carcinoma, and a multi-tumor canine tissue array.  Arrays in development include one for canine mammary cancer and one for canine prostate cancer. These array reagents have and will be useful for identifying therapeutic targets in canine cancers, and for the study of cancer and metastasis biology.

2) Develop a multi-center collaborative network with extramural comparative oncology programs.  Within this network we design, implement and manage pre-clinical trials involving pet animals that will evaluate novel therapeutic strategies for cancer:

  • Comparative Oncology Trial Consortium (COTC).  The Comparative Onoclogy Program has used its neutral leadership position to bring together several top-notch schools of veterinary medicine to collaborate as a multi-center clinical trial network.  This network works together through the Comparative Oncology Program to offer NCI investigators, the pharmaceutical industry, and the broader academic community the opportunity to inform their cancer drug development paths by using naturally occurring cancers in dogs as models for drug development.

3) Increase the awareness of the appropriate use of naturally occurring cancer models within the cancer research community.

Scientific Focus Areas:
Cancer Biology, Cell Biology

Publications

Selected Recent Publications
  1. El Touny LH, Vieira A, Mendoza A, Khanna C, Hoenerhoff MJ, Green JE
    J Clin Invest. 124: 156-68, 2014. [ Journal Article ]
  2. Paoloni M, Webb C, Mazcko C, Cherba D, Hendricks W, Lana S, Ehrhart EJ, Charles B, Fehling H, Kumar L, Vail D, Henson M, Childress M, Kitchell B, Kingsley C, Kim S, Neff M, Davis B, Khanna C, Trent J
    PLoS ONE. 9: e90028, 2014. [ Journal Article ]
  3. Heinecke JL, Ridnour LA, Cheng RY, Switzer CH, Lizardo MM, Khanna C, Glynn SA, Hussain SP, Young HA, Ambs S, Wink DA
    Proc Natl Acad Sci U S A. 111: 6323-8, 2014. [ Journal Article ]
  4. Mendoza A, Gharpure R, Dennis J, Webster JD, Smedley J, Khanna C
    J Am Assoc Lab Anim Sci . 52: 584-9, 2013. [ Journal Article ]
  5. Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, Barkauskas DA, Marina N, de Toledo SR, Petrilli AS, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter DJ, Malats N, Kogevinas M, Wacholder S, Troisi R, Helman L, Fraumeni JF, Yeager M, Hoover RN, Chanock SJ
    Nat Genet. 45: 799-803, 2013. [ Journal Article ]

Biography

Dr. Khanna is a graduate of the Western College of Veterinary Medicine in Saskatoon, Saskatchewan. His specialty training included a small animal medicine and surgery internship at the Ontario Veterinary College in Guelph, Ontario, followed by a residency in veterinary internal medicine and oncology at the University of Minnesota. Dr. Khanna is board-certified with the American College of Veterinary Internal Medicine (oncology). His training in cancer research includes a Ph.D. in pathobiology from the University of Minnesota, where he studied the immunotherapy of metastatic cancers, and a senior staff fellowship at the National Institutes of Health (NIH) in Bethesda Maryland. 

Dr. Khanna's primary area of interest is the biology and treatment of cancer metastasis. Dr. Khanna has been able to couple his training in veterinary oncology with his interests in cancer research through the development  of the Comparative Oncology Program, within the NCI Center for Cancer Research. This program aims to improve outcomes for cancer patients through the integration of pet animals with cancer into the study of cancer biology and treatment. Dr. Khanna is Chair of the Biology Subcommittee of the Children's Oncology Group, a founding member of the Canine Comparative Oncology and Genomics Consortium, and President-elect of the American College of Veterinary Internal Medicine - Oncology.